专题：Hidradenitis Suppurativa and Treatments

This cluster of papers focuses on the treatment, pathogenesis, and comorbidities of Hidradenitis Suppurativa (HS), also known as Acne Inversa. It covers topics such as inflammatory pathways, genetic susceptibility, metabolic syndrome, and the impact of HS on quality of life. The cluster also discusses various therapeutic approaches including immunosuppressive therapy and TNF-alpha inhibitors.
最新文献
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

article Full Text OpenAlex

A young woman’s experience of surgery for severe hidradenitis suppurativa

article Full Text OpenAlex

A novel mutation in a craniofacial pustular pyoderma gangrenosum patient with secondary hemophagocytic lymphohistiocytosis

letter Full Text OpenAlex

IgG4 serologic elevation in a patient with severe hidradenitis suppurativa: a case report and review of the literature

article Full Text OpenAlex

Atypical cause of radiating leg pain: Visceral referred pain due to ulcerative colitis

article Full Text OpenAlex

A Clinicodemographic Study of Indian Patients with Hidradenitis Suppurativa and its Association with Metabolic Syndrome

article Full Text OpenAlex

Isolated Terminal Ileitis- Crohn’s Disease or Something Else?

article Full Text OpenAlex

Hidradenitis Suppurativa Reduces Quality of Life for Skin of Colour Patients

letter Full Text OpenAlex

Innovations in Hidradenitis Suppurativa

review Full Text OpenAlex

S3956 Fork in the Road: Fistulizing Perianal Crohn’s Disease and Hidradenitis Suppurativa

article Full Text OpenAlex

近5年高被引文献
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

article Full Text OpenAlex 253 FWCI127.53285029

Antimicrobial Potential of Curcumin: Therapeutic Potential and Challenges to Clinical Applications

review Full Text OpenAlex 231 FWCI24.11251566

Prevalence of Hidradenitis Suppurativa

review Full Text OpenAlex 203 FWCI35.48187391

Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments

review Full Text OpenAlex 189 FWCI41.74241915

Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations

review Full Text OpenAlex 186 FWCI34.9483119

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

article Full Text OpenAlex 152 FWCI32.28050183

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

article Full Text OpenAlex 135 FWCI25.87775767

Dermatological Manifestations in Inflammatory Bowel Diseases

review Full Text OpenAlex 115 FWCI16.05437427

The Genomic Architecture of Hidradenitis Suppurativa—A Systematic Review

review Full Text OpenAlex 113 FWCI24.30022483

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

article Full Text OpenAlex 111 FWCI131.73394088